Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1016/j.cell.2012.03.031">http://dx.doi.org/10.1016/j.cell.2012.03.031</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Wed Jan 23 18:44:23 EST 2019</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/91688">http://hdl.handle.net/1721.1/91688</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

Michael J. Lee,1,2 Albert S. Ye,2,3 Alexandra K. Gardino,1,2 Anne Margriet Heijink,1 Peter K. Sorger,2,4 Gavin MacBeath,2,4 and Michael B. Yaffe1,2,*

1Departments of Biology and Biological Engineering, David H. Koch Institute for Integrative Cancer Research  
2Cell Decision Processes Center  
Massachusetts Institute of Technology, Cambridge, MA 02139, USA  
3Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA  
4Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA  
*Correspondence: myaffe@mit.edu  
DOI 10.1016/j.cell.2012.03.031

SUMMARY

Crosstalk and complexity within signaling pathways and their perturbation by oncogenes limit component-by-component approaches to understanding human disease. Network analysis of how normal and oncogenic signaling can be rewired by drugs may provide opportunities to target tumors with high specificity and efficacy. Using targeted inhibition of oncogenic signaling pathways, combined with DNA-damaging chemotherapy, we report that time-staggered EGFR inhibition, but not simultaneous coadministration, dramatically sensitizes a subset of triple-negative breast cancer cells to genotoxic drugs. Systems-level analysis—using high-density time-dependent measurements of signaling networks, gene expression profiles, and cell phenotypic responses in combination with mathematical modeling—revealed an approach for altering the intrinsic state of the cell through dynamic rewiring of oncogenic signaling pathways. This process converts these cells to a less tumorigenic state that is more susceptible to DNA damage-induced cell death by reactivation of an extrinsic apoptotic pathway whose function is suppressed in the oncogene-addicted state.

INTRODUCTION

Standard therapies for the treatment of human malignancies typically involve the use of chemotherapy or radiation therapy, which function by damaging DNA in both normal and cancerous cells (Lichter and Lawrence, 1995). Our growing understanding of this process suggests that the DNA damage response (DDR) functions as part of a complex network controlling many cellular functions, including cell cycle, DNA repair, and various forms of cell death (Harper and Elledge, 2007). The DDR is highly interconnected with other progrowth and prodeath signaling networks, which function together to control cell fate in a nonlinear fashion due to multiple levels of feedback and crosstalk. Thus, it is difficult to predict a priori how multiple, often conflicting signals will be processed by the cell, particularly by malignant cells in which regulatory networks often exist in atypical forms. Predicting the efficacy of treatment and the optimal design of combination therapy will require a detailed understanding of how the DDR and other molecular signals are integrated and processed, how processing is altered by genetic perturbations commonly found in tumors, and how networks can be “rewired” using drugs individually and in combination (Sachs et al., 2005).

In many forms of breast cancer, aberrant hormonal and/or growth factor signaling play key roles in both tumor induction and resistance to treatment (Hanahan and Weinberg, 2000). Moreover, the identification of molecular drivers in specific breast cancer subtypes has led to the development of more efficacious forms of targeted therapy (Schechter et al., 1984; Slamon et al., 1987). In spite of these advances, there are currently no targeted therapies and no established molecular etiologies for triple-negative breast cancers (TNBC), which are a heterogeneous mix of breast cancers defined only by the absence of estrogen receptor (ER) or progesterone receptor (PR) expression and lack of amplification of the HER2 oncogene (Perou et al., 2000). Patients with TNBCs have shorter relapse-free survival and a worse overall prognosis than other breast cancer patients; however, they tend to respond, at least initially, to genotoxic chemotherapy (Dent et al., 2007). Triple-negative patients generally do well if pathologic complete response is achieved following chemotherapy. When residual disease exists, however, the prognosis is typically worse than for other breast cancer subtypes (Abeloff et al., 2008). Thus, identifying new strategies to enhance the initial chemosensitivity of TNBC cells may have substantial therapeutic benefit. We wondered whether a systems biology approach, focused on examining and manipulating the interface between growth factor signaling pathways and DNA damage signaling pathways in tumor cells, could
modulate the therapeutic response of this recalcitrant tumor type. We report here that pretreatment, but not cotreatment or posttreatment, of a subset of TNBCs with Epidermal Growth Factor Receptor (EGFR) inhibitors can markedly synergize their apoptotic response to DNA-damaging chemotherapy through dynamic rewiring of oncogenic signaling networks and unmasking of suppressed proapoptotic pathways. These results may have broader implications for the testing, design, and utilization of combination therapies in the treatment of malignant disease.

RESULTS

A Critical Order and Time Dependency for Enhanced EGFR Inhibition/DNA Damage-Mediated Cell Death

Signaling networks can respond to, and can be functionally rewired by, exposure to specific ligands or drugs (Janes et al., 2005, 2008). It is increasingly clear that these responses are time dependent. We reasoned that it should, in principle, be possible to dynamically rewire the DDR network in an insensitive cell through prior exposure to a drug that modulates the network, thereby rendering the cell sensitive to DNA-damaging agents. To test this hypothesis, we systematically investigated a series of drug combinations for synergism or antagonism in breast cancer cells using protocols that changed both the order and timing of drug addition.

We combined genotoxic agents with small molecule inhibitors targeting common oncogenic signaling pathways (Figure 1A). We included drugs that are known to be clinically useful in other cancers but are known to lack efficacy in TNBC individually or in combination (Bosch et al., 2010; Winer and Mayer, 2007). Previous studies using cell culture models of TNBC, for example, reported that EGFR inhibitors in combination with genotoxic compounds such as cisplatin resulted in less than a 10% survival benefit (Corkery et al., 2009), whereas a randomized phase II trial in TNBC patients reported that addition of cetuximab to carboplatin did not improve outcome (Carey et al., 2008). However, emerging understanding of the complex nonlinear and time-dependent interplay between signaling networks argues that a more systematic assessment exploring not only dosage, but also the order of drug presentation, scheduling, and dose duration might uncover cross-pathway effects and efficacious interactions that were missed previously (Fitzgerald et al., 2006). An initial combination screen was therefore performed in a panel of canonical breast cancer cell lines representing those that are hormone sensitive (MCF7), HER2 overexpressing (MDA-MB-453), or triple negative (BT-20) (Neve et al., 2006). A first pass of the screen, scoring for viability, was performed in BT-20 cells, and a subset of combinations was then explored more thoroughly, scoring for viability, proliferation, and apoptotic responses in the panel of three cell lines (Figures S1B–1E and Figure S1 available online).

Consistent with previous reports, we found that inhibition of EGFR using the compound erlotinib (ERL) was not a potent apoptotic stimulus in TNBC cells when used alone or when added at the same time as or shortly before doxorubicin (DOX) (Figure 1B, left bars 1–6). Surprisingly, however, combinations in which erlotinib was added at least 4 hr prior to doxorubicin showed a markedly enhanced apoptotic response, with cell killing increasing by as much as 500% (Figure 1B, middle bars 7–10). When the order of drug presentation was reversed—doxorubicin given before erlotinib—cell killing was not enhanced relative to treatment with doxorubicin or erlotinib alone (Figure 1B, right bars 11 and 12). The efficacy of the time-sequenced erlotinib-doxorubicin treatment was analyzed for doxorubicin dose-effect relationships using the Chou-Talalay method (Chou and Talalay, 1984) and was found to vary significantly across breast cancer subtypes (Figures 1C–1E and 1G). Whereas chronic EGFR inhibition was synergistic with doxorubicin in killing TNBC BT-20 cells, the same treatment regimen antagonized doxorubicin sensitivity in HER2-overexpressing MDA-MB-453 cells. All temporal erlotinib-doxorubicin combinations tested were merely additive in luminal MCF7 cells. The order and timing of drug addition had little effect in Hs578Bst, a cell line derived from normal peripheral breast tissue, which was generally drug resistant (Figure 1F).

Furthermore, this enhanced treatment effect in BT-20 cells was not limited to combinations of doxorubicin and erlotinib. Synergistic killing was also observed following time-staggered pretreatment of BT-20 cells with either erlotinib, gefitinib, or lapatinib (all EGFR inhibitors) in combination with the DNA-damaging agent camptothecin, as well as with doxorubicin (Figures S1A–S1C) (Wood et al., 2004).

Sustained EGFR Inhibition Suppresses Oncogenic Signatures and Rewires the Intrinsic State of the Tumor Cells to a More Chemosensitive Form

Although erlotinib inhibits EGFR and downstream signaling within minutes (Figures S2A and S2B), enhanced cell death in response to DNA-damaging agents required pretreatment with erlotinib for several hours. To verify that this was indeed due to on-target inhibition of EGFR, in addition to testing other EGFR inhibitors (above), we knocked down EGFR using two different small interfering RNAs (siRNAs). Like the time-staggered erlotinib-doxorubicin treatment, strong proapoptotic responses were observed in BT-20 cells following EGFR knockdown with delayed doxorubicin treatment (Figures 1H and 1I). Importantly, the addition of erlotinib to EGFR knockdown cells had no additional effect, arguing against an off-target effect of the drug. As a further test, we also examined coadministration of higher concentrations of erlotinib instead of time-staggered doses without observing increased apoptosis (Figure S2C). Taken together, these data indicate that enhanced cell death observed using time-staggered erlotinib-doxorubicin combinations is directly mediated by sustained EGFR inhibition.

Potential explanations for the increased sensitivity of cells to doxorubicin following sustained EGFR inhibition include modulation of cell-cycle progression, altered rates of doxorubicin influx/efflux, or changes in levels of DNA damage itself. To examine these, we monitored cell-cycle progression at five time points over 24 hr in our panel of breast cancer cell lines. Although doxorubicin and erlotinib altered cell-cycle dynamics depending on the cell type, cells that received both drugs had similar cell-cycle profiles regardless of the dosing regimen (Figures 2A–2D and S2D). In particular, there is no evidence that cells exposed to the ERL→DOX protocol accumulate in S/G2, the cell-cycle stage during which doxorubicin may be most effective. Thus,
Figure 1. A Screen for Novel Combination Treatment Reveals Dosing Schedule-Dependent Efficacy for Killing TNBC Cells

(A) Schematic of combinations tested. Seven genotoxic drugs and eight targeted signaling inhibitors were tested in pair-wise combinations, varying dose, order of presentation, dose duration, and dosing schedule.

(B) Apoptosis in BT-20 cells. Cleaved-caspase 3/cleaved-PARP double-positive cells were quantified using flow cytometry (bottom). In cells treated with DMSO, erlotinib (ERL), or doxorubicin (DOX), apoptosis measurements were performed 8 hr after drug exposure or at the indicated times. D/E, ERL → DOX, and DOX → ERL refer to DOX and ERL added at the same time, ERL given at the indicated times before DOX, and DOX given at the indicated times before ERL, respectively. For each, apoptotic measurements were made 8 hr after the addition of DOX. Erlotinib and doxorubicin were used at 10 μM. Mean values ±SD of three independent experiments, each performed in duplicate, are shown (top).

(C–F) Apoptosis in different subtypes of breast cancer. Apoptosis was measured as in (B). (D and E) E/L and D/E refer to DOX and ERL added at the same time, ERL given 24 hr before DOX, and DOX given 24 hr before ERL, respectively. Data are mean values ±SD of three independent experiments.

(G) Dose-response profiles of erlotinib/doxorubicin drug combinations. Apoptosis was measured as in (B). Drugs were added at a 1:1 ratio, and combination index (CI) was calculated according to the Chou-Talalay method.

(H) Knockdown of EGFR in BT-20 cells measured 48 hr after addition of the indicated siRNA by immunoblotting (left). EGFR expression relative to “no RNA” control is quantified on right. Data shown are the mean ±SD of both siRNAs, each performed in biological duplicate.

See also Figure S1.
cell-cycle modulation cannot explain the unique efficacy of sequential drug exposure. Some membrane pumps can be modulated by EGFR inhibitors (Lopez et al., 2007; Turner et al., 2006) and are responsible for multidrug resistance in at least some breast cancers (Woehlecke et al., 2003). We therefore measured the intracellular accumulation of doxorubicin by flow cytometry and found that prior treatment with erlotinib did not alter the intracellular doxorubicin concentration (Figures 2E–2H). Next, as pharmacodynamic markers of doxorubicin action, we assayed two indicators of DNA double-stranded breaks: phosphorylation of histone H2AX at S139 and formation of 53BP1-containing nuclear foci. Both assays showed similar responses across all treatment conditions (Figures 2I–2K). Taken together, these data indicate similar levels of DNA damage and early DNA damage-related signaling in DOX- and ERL/DOX-treated cells independent of the efficacy of the combination in cell killing.

The absence of demonstrable changes in cell-cycle states, intracellular doxorubicin concentrations, or doxorubicin-induced DNA damage suggested that prolonged EGFR inhibition necessary for effective tumor cell killing might result from rewiring of the signaling networks that control responses to genotoxic stress. To investigate this idea, we measured changes in gene expression in cells treated with erlotinib alone. In triple-negative BT-20 cells, EGFR inhibition for 30 min resulted in few differentially expressed genes (DEGs) (Figure S3A). Following 6 hr of erlotinib treatment, however, we observed >1,200 DEGs, and following 24 hr of treatment, when doxorubicin sensitivity was maximally enhanced, we observed >2,000 DEGs (Figures 3A and S3B). By comparison, in the HER2+ MDA-MB-453 cells, which were desensitized to doxorubicin by erlotinib exposure, we observed only 235 DEGs following 24 hr exposure to erlotinib, and in hormone-sensitive MCF7 cells, only one gene was significantly altered (Figures 3B and 3C). Thus, the triple-negative BT-20 cells exhibited progressive and large-scale changes in gene expression following EGFR inhibition that were not observed in cell lines insensitive to the time-staggered ERL/DOX combination.
Figure 3. Triple-Negative BT-20 Cells Are Driven by Oncogenic EGFR Signaling
(A–C) DEGs following erlotinib treatment for 24 hr versus untreated cells. Cut-off for DEG was \( \geq 2\)-fold change and a p-value \( \leq 0.05 \) (genes that meet both criteria are colored red). B score is the log of the odds of differential expression.

(D) DEGs classified using GeneGO “pathway maps.” Heatmap (left) colored according to \(-\log(p\text{ value})\); (right) p-value cut-off was 0.05 (dotted red line).

(E and F) Microarray analysis using GSEA reveals loss of oncogene signatures in BT-20 cells after sustained EGFR inhibition. Ras oncogenic signature and false discovery rate (FDR)-adjusted p values are shown in (E). Eleven oncogenic signatures from the Molecular Signatures Database (MSigDB) are shown in (F). Boxes are colored according to normalized enrichment score (NES).
To examine which cellular processes were altered by long-term erlotinib treatment, DEGs in BT-20 cells were categorized by cellular process according to the GeneGO pathway annotation software (Ekins et al., 2007). Significant changes were observed in 16 of 34 GeneGO cellular networks, including those that mediate the DDR, apoptosis, and inflammation (Figure 3D). In contrast, DEGs in MDA-MB-453 were not only fewer in number, but also lay in networks that did not overlap with those altered in BT-20 cells (Figure 3D). We further analyzed gene expression data using gene set enrichment analysis (GSEA), a tool for identification of enrichment or depletion of defined gene expression signatures within a rank-ordered gene list (Subramanian et al., 2005). The most statistically significant changes in BT-20 cells upon sustained erlotinib exposure were loss of the Ras and MYC oncogenic signatures (Figure 3E). These signatures were not significantly altered in MDA-MB-453 or MCF7 cells treated with erlotinib for 24 hr or in BT-20 cells exposed to erlotinib for 30 min (Figure 3E). Within the GSEA molecular signatures database, there exist 11 oncogenic signatures (Subramanian et al., 2005). GSEA of EGFR-inhibited BT-20 cells showed a similar depletion pattern for all 11 oncogenic signatures (Figure 3F). These changes were not consistently observed in either MDA-MB-453 cells or MCF7 cells following exposure to erlotinib.

Distinct gene expression patterns have been used to define breast cancer subtypes. BT-20 cells, like most triple-negative cells, display a “basal-like” gene expression signature (Neve et al., 2006). Strikingly, analysis of our expression data set revealed that chronic erlotinib treatment of BT-20 cells caused progressive time-dependent loss of basal-like gene expression with concomitant gain in luminal A-like gene expression, a breast cancer subtype with the least aggressiveness and best overall prognosis (Figure 3G). In contrast, no such switch in breast cancer subtype patterns of gene expression was observed in HER2-overexpressing MDA-MB-453 cells or hormone-sensitive MCF7 cells following erlotinib exposure.

These expression data suggest that the oncogenic potential of BT-20 cells is maintained by chronic EGFR-driven patterns of gene expression and that this cell state could be remodeled through sustained inhibition of EGFR. To directly test this, we examined the ability of BT-20 cells to form colonies in soft agar, a classic test of transformation that typically shows good correlation with tumorigenic potential in vivo (Montesano et al., 1977). Consistent with the predictions derived from our GSEA, sustained EGFR inhibition with erlotinib potently inhibited soft agar colony formation (Figure 3H).

Creation of a Data-Driven Model for Combined EGFR Inhibition/DNA Damage

To better understand the biochemical changes in signaling that accompany time-staggered ERL→DOX treatment, we used quantitative high-throughput reverse-phase protein microarrays and quantitative western blotting to measure the levels or activation states of 35 signaling proteins within multiple signaling pathways at 12 time points following exposure to erlotinib and doxorubicin both individually and in combination (Figures 4A–4D and see Figure S4 for a description of the selection of 35 proteins for analysis) (MacBeath, 2002). Oncogenic signaling networks typically exhibit multiple levels of feedback and crosstalk with other networks, rendering single protein measurements ineffective in predicting complex cellular responses to drugs such as those leading to DNA damage-induced apoptosis (Fitzgerald et al., 2006). We therefore constructed a multifactorial data-driven mathematical model relating signaling “inputs” to phenotypic “outputs.” In addition to examining signaling pathways known to contribute to the DDR, we used our list of differentially expressed genes (Figure 3) to identify other proteins that might function as critical signaling nodes. This DEG-expanded list of signaling proteins extends far beyond the canonical components of the DDR, including proteins involved in apoptotic and nonapoptotic death, growth and stress responses, and cytokine/inflammatory signaling (Figure S4A). Specific proteins, whose measurement was motivated by gene expression data, included Bcl2-interacting mediator of cell death (BIM), BH3-interacting domain (BID), capase-8, 4E-BP1, S6K, Stat3, DUSP6, and inhibitor of kappa B (IKB). Phenotypic responses, including cell-cycle arrest and progression, autophagy, and apoptotic and nonapoptotic cell death, were scored at six time points using luminescent microplate assays, flow cytometry, and automated microscopy (Figures 4E and S4C–S4F). All signaling and phenotypic response measurements were performed in biological and experimental triplicate in BT-20, MDA-MB-453, and MCF7 cells. In total, this data set comprised more than 45,000 measurements of molecular signals and 2,000 measurements of cellular responses (Figures 4A and 4E), revealing many changes in cell state and phenotype associated with drug exposure.

Several mathematical modeling approaches were employed to relate signaling data to cell phenotypes. Initial modeling efforts used principal component analysis (PCA) to identify covariation between signals, whereas partial least-squares (PLS) regression was used to identify statistically significant covariation between molecular signals and corresponding cellular responses (Figures S4B) (Janes and Yaffe, 2006). In both PCA and PLS modeling, vectors were constructed whose elements contained quantitative measures of the level, state, and/or activity of specific signaling proteins. The vectors were then reduced to a set of principal components, calculated so that each additional PCA or PLS dimension maximally captures information not captured by preceding components. This process was iteratively repeated until additional principal components ceased to capture meaningful data, as judged relative to experimental noise.

(G) GSEA reveals a switch from basal to luminal A genetic signature in BT-20 cells following sustained EGFR inhibition. Expression analyzed as in (F) using breast cancer subtype-specific genetic signatures as defined by Sørlie et al. (2001).

(H) BT-20 cells lose the ability to form colonies in soft agar upon EGFR inhibition. Cells were untreated or treated with ERL, grown in soft agar, and monitored for colony formation 21 days later.

See also Figure S3.
Following PCA, multiplex data from MDA-MB-453 cells projected negatively along principal component one (PC1), data from BT-20 cells projected positively along PC1, and MCF7 data were largely neutral (Figures 5A and S5A). Thus, the first principal component captured cell type-specific variance in the data. In contrast, data from all cell types projected similarly along PC2 but in a manner that was drug dependent. Data from DMSO- or erlotinib-treated cells not exposed to doxorubicin projected negatively along PC2, whereas data from cells cotreated with doxorubicin and erlotinib or exposed sequentially to ERL → DOX projected positively along PC2. Finally, data from cells treated with doxorubicin alone or DOX → ERL were largely neutral along PC2. Thus, the second principal component captured signaling variance from treatment-specific modulation of the signaling networks regardless of cell type (Figure 5A).

These data suggest that, although significant differences in the state of the networks exist between cell lines, the drugs that we applied modulated signaling networks in similar ways across...
all lines examined. PLS analysis linking signals to responses gave similar results, with differences between the cell lines now captured in both PC1 and PC2 and treatment-specific variance emerging in the third principal component, PC3 (Figures 5B and S5B–S5E). The expected differences that we observed between these cell types, captured by both PCA and PLS analyses, confirm that the signaling molecules we measured can be used to define both the cell-type-specific and drug treatment-specific differences between these cells.

Based on these cell-type-specific differences in the global PCA/PLS model, we next built models for each cell line in isolation, focusing primarily on triple-negative BT-20 cells. To optimize the BT-20 PLS model, we compared fitness measures such as $R^2$ (percent of variance captured by model), $Q^2$ (percent of variance predicted by the model using a leave-one-out cross-validation approach), and root-mean-square error (rmse; the mean deviation between model and data) across models containing increasing numbers of principal components. With BT-20 data alone, >97% of the variance linking signals to responses under different conditions of drug treatment was captured by two principal components. Incorporation of additional components actually reduced the predictive ability of the

Figure 5. A PLS Model Accurately Predicts Phenotypic Responses from Time-Resolved Molecular Signals

(A) Principal components analysis of covariation between signals. Scores plot represents an aggregate measure of the signaling response for each cell type under each treatment condition at a specified time, as indicated by the colors and symbols in the legend. (B and C) Scores and loadings for a PLS model. (B) Scores calculated and plotted as in (A), except the principal components now reflect covariation between signals and responses. (C) PLS loadings plotted for specific signals and responses projected into principal component space. (D–I) BT-20 cell line-specific model calibration. (D) $R^2$, $Q^2$, and RMSE for BT-20 models built with increasing numbers of principal components. (E and F) Scores and loadings plots, respectively, for a two-component model of BT-20 cells. (G–I) Apoptosis as measured by flow cytometry or as predicted by our model using jack-knife cross-validation. $R^2$ reports model fit, and $Q^2$ reports model prediction accuracy. (G) Final refined model of apoptosis in BT-20. (H) BT-20 model minus targets identified as DEGs in microarray analysis. (I) Model using only the top four signals: c-caspase-8, c-caspase-6, p-DAPK1, and pH2AX.

See also Figure S5.
model (Figure 5D), a common finding reflecting the addition of noise when components with little predictive value are added. Similar trends were observed for each of the other cell lines. To derive molecular understanding from the models, we projected the loading vectors (i.e., individual signals and responses) into PLS component space. We observed a strong anticorrelation between the apoptotic and proliferative responses (Figures 5C and 5F) that was captured by the first principal component in the BT-20 model (Figure 5F) and by the second principal component in the aggregate cell line model (Figure 5C). To further test model quality, we compared each measured cellular response in isolation to that predicted by the model using jackknife-based cross-validation (Figures S5F–S5L). Our model was particularly accurate at predicting apoptosis following treatment (Figure 5G) and was moderately good at predicting proliferation and autophagy (Figures S5K and S5L). Other responses (G1, G2, and S) were not predicted as accurately, likely due to the limited dynamic range in our cell-cycle response data set (Figures S5G–S5J).

PLS Modeling Reveals that Chemosensitization following Network Rewiring Is Driven by Caspase-8 Activation

Because PLS models of individual cell lines could accurately predict apoptosis, we analyzed the models to identify specific proteins or signals that might account for the enhanced sensitivity of BT-20 cells to doxorubicin following EGFR inhibition. The BT-20 two-component PLS model identified four signals (cleaved caspase-8, cleaved-caspase-6, phospho-DAPK1, and phospho-H2AX) that were highly covariant with apoptosis (Figure 5F). Remarkably, a model including only these four signals was just as accurate at predicting apoptosis as the complete 35-signal model (Figures 5G–5I). Notably, of these signals, only caspase-8 was just as accurate at predicting apoptosis as the complete 35-signal model (Figures 5G–5I). To test these predictions experimentally, two separate caspase-8 siRNAs were used in both BT-20 cells and MDA-MB-453 cells (Figures 6D and 6E). In excellent agreement with the model, knockdown of caspase-8 mitigated the enhanced cell death following erlotinib treatment in BT-20 cells while having minimal effect on apoptosis following other treatment combinations (Figure 6F). Furthermore, caspase-8 knockdown had little effect on apoptosis in MDA-MB-453 under any condition (Figure 6G).

To further assess model predictions and evaluate the relative importance of caspase-8 in the enhanced doxorubicin-induced apoptosis, we tested several other model-generated predictions, including proteins predicted to contribute strongly to apoptosis (caspase-6), moderately (Beclin-1), or weakly (RIP1) to apoptosis in BT-20 cells. Based on the VIP plot and loadings projections, caspase-8 is predicted to be a strong driver of the apoptotic response in BT-20 and MDA-MB-453 cells, but not MCF7 cells; Beclin-1 is predicted to be moderately antiapoptotic in BT-20 cells but has no role in the other cell lines; and RIP1 is predicted to be weakly antiapoptotic in BT-20 and MDA-MB-453 cells but strongly antiapoptotic in MCF7 cells. As shown in Figure S6, we were able to confirm these cell type dependences using siRNA and confirm the relative magnitude of the effect of each target on the apoptotic response following various combinations of erlotinib and/or doxorubicin. Importantly, although caspase-6 contributed strongly to cell death in BT-20 cells, caspase-8 remained the strongest predictor. None of the other targets tested modulated the apoptotic response to the same extent as caspase-8, further highlighting its importance. Thus, the increased cell killing by ERL/DOX treatment in BT-20 cells appears to involve rewiring of the DNA damage response, allowing activation of both cell-intrinsic and -extrinsic apoptotic programs to contribute to cell death.

Time-Staggered Inhibition of EGFR Enhances Apoptotic Response in a Subset of TNBC Cells and Other Oncogene-Driven Cells

To examine whether the efficacy of time-staggered ERL/DOX treatment was unique to BT-20 cells or potentially a more general phenomenon of TNBC cells, we examined a handful of other triple-negative cell lines (Neve et al., 2006). The selected cell lines have markedly different growth rates, EGFR expression levels, and p53 states (Figure S7A). Despite these differences, sustained EGFR inhibition enhanced sensitivity to doxorubicin in nine of ten triple-negative cell lines tested. A synergistic effect, however, was observed in only four of the ten TNBC lines (Figures 7A, S7A, and S7B). To identify potential reasons for this, we measured total EGFR protein levels and basal EGFR activation by immunoblotting. Our quantitative measurement of EGFR protein expression was very similar to previously reported values (Neve et al., 2006) and correlated only very weakly with sensitivity to ERL/DOX treatment (Figures 7A and 7B). In marked contrast, the levels of basal EGFR activity exhibited...
a much higher correlation (Figures 7A and 7B). Furthermore, in those TNBC cell lines in which ERL/DOX treatment was synergistic, we consistently observed caspase-8 cleavage following sequential administration, but not other drug treatments, suggesting a similar mechanism of enhanced apoptosis in these cells as that observed in BT-20 cells (Figures 7A and 7B). Taken in context with our observation that EGFR signaling drives expression of an oncogenic gene expression signature in BT-20 cells, these findings suggest that a subset of triple-negative cell lines are similarly driven by aberrant EGFR signaling. Importantly, however, these cells could not be distinguished by measuring EGFR gene amplification or EGFR abundance. Instead, they are unique in displaying high levels of activated (phosphorylated) EGFR as a biomarker of response to time-staggered EGFR inhibition and cytotoxic treatment.

We next investigated whether the initial chemosensitizing effects of an ERL→DOX protocol could be observed when treating EGFR-driven triple-negative tumors in vivo. BT-20 cells were injected into the flanks of nude mice, and tumors were allowed to form for 7 days before treatment with either doxorubicin alone or erlotinib-doxorubicin combinations. Following a single dose of doxorubicin alone, a marked reduction in tumor volume was observed over the first 3 days after treatment. The residual tumors continued to grow, however, reaching pretreatment volume after ~14 days (Figure 7C). A similar trend was observed for tumors cotreated with erlotinib and doxorubicin, although the initial reduction in tumor size was greater. In contrast, when mice were given erlotinib 8 hr prior to doxorubicin, the tumors not only exhibited a similar initial reduction in size, but also failed to regrow throughout the 14 day monitoring period. Thus, the chemosensitizing effect of sequential ERL/DOX treatment seen in culture was also observed in vivo. These results suggest that time-staggered inhibition of EGFR, in combination with DNA damaging agents, could be a potentially useful therapeutic strategy for treating a subset of triple-negative tumors, particularly those with high basal levels of phosphorylated EGFR.

Figure 6. Enhanced Sensitivity to Doxorubicin Is Mediated by Caspase-8 Activation

(A) VIP scores for predicting apoptosis plotted for each cell line-specific PLS model. VIP score >1 indicates important x variables that predict y responses, whereas signals with VIP scores <0.5 indicate unimportant x variables.

(B and C) Model-generated predictions of apoptosis with (blue) or without (red) caspase-8 activation 8 hr after the indicated treatments in BT-20 (B) and 453 (C).

(D and E) Western blot verifying caspase-8 knockdown in BT-20 (D) and 453 (E).

(F and G) Measured apoptosis 8 hr after the indicated treatment in cells expressing control RNA or caspase-8 siRNA. (F) BT-20. (G) 453. In both (F) and (G), apoptotic values represent mean response ±SD from both siRNAs, each in duplicate.

See also Figure S6.
We next examined whether the principle of time-staggered inhibition would sensitize other breast cancer subtypes to doxorubicin. In contrast to BT-20 cells, MDA-MB-453 cells were not sensitized by sustained EGFR inhibition but instead were desensitized to DNA-damaging chemotherapy (Figure 1D). However, MDA-MB-453—and other widely used cell lines like BT-474—have a well-established oncogene addiction to HER2 (Neve et al., 2006). We therefore tested time-staggered inhibition of HER2 using the drug lapatinib (a potent inhibitor of both EGFR and HER2) in combination with doxorubicin in these cells. In both MDA-MB-453 and BT-474 cells, in contrast to the desensitization caused by pretreatment with erlotinib, we observed that lapatinib pretreatment enhanced sensitivity to doxorubicin to a similar extent as the enhancement observed with erlotinib in BT-20 and other EGFR-driven TNBC cells (Figures 7C and S7C). Importantly, whereas all temporal combinations of lapatinib and doxorubicin were synergistic in HER2-overexpressing cells, pretreatment with lapatinib resulted in the largest increase in apoptosis. Furthermore, caspase-8 cleavage was only observed following LAP→DOX treatment of HER2-driven cells, but not by other drug combinations. Knockdown of caspase-8 in these cells eliminated the specific component of enhanced cell death observed only in the pretreatment condition (Figures 7C and S7C), suggesting that this portion of the overall cell death was driven by caspase-8 activity.

Finally, we examined whether the efficacy of time-staggered inhibition of EGFR was limited to breast cancer cells. Many lung cancers, for example, contain either high levels of phosphorylated wild-type EGFR or mutations within EGFR itself. We therefore tested our ERL→DOX treatment protocol on NCI-H1650 cells, a lung cancer cell that contains an in-frame deletion that is commonly seen in lung cancers (Sordella et al., 2004), as well as on A549 and NCI-H358, cells that have high levels of phosphorylated wild-type EGFR, possibly due to HER2 amplification (Baliko et al., 2006; Diaz et al., 2010; Helfrich et al., 2007; Rusnak et al., 2007). Remarkably, in all three lung cancer cell lines, we found that time-staggered inhibition of EGFR using erlotinib caused a dramatic sensitization to killing by doxorubicin that was associated with caspase-8 cleavage (Figures 7E, 7F, and S7D). Furthermore, knockdown of caspase-8 largely abrogated the enhanced cell death observed in the pretreatment condition, exactly as was seen in the setting of TNBCs. Thus, time-staggered inhibition of EGFR in cells with highly active EGFR signaling may be a generalizable approach to potentiate the effects of DNA damaging chemotherapy.

**DISCUSSION**

In this study, we describe a systematic time- and dose-dependent approach to identifying drug combinations that are efficacious in killing cancer cells, depending on changes in the order and duration of drug exposure. We found that EGFR inhibition dramatically sensitizes a subset of TNBCs to DNA damage if the drugs are given sequentially, but not simultaneously. Furthermore, our transcriptional, proteomic, and computational analyses of signaling networks and phenotypes in drug-treated cells revealed that the enhanced treatment efficacy results from dynamic network rewiring of an oncogenic signature maintained by active EGFR signaling to unmask an apoptotic process that involves activation of caspase-8. The enhanced sensitivity to damaging agents that we observed required sustained inhibition of EGFR because the phenotype did not result from the rapid, direct inhibition of the oncogene but, rather, from modulation of an oncogene-driven transcriptional network as indicated schematically in the model shown in Figure 7G. Furthermore, our data suggest that it is activity of the EGFR pathway, rather than EGFR expression per se, that determines whether time-staggered inhibition will result in synergistic killing. Because EGFR can be activated through a diverse set of genetic alterations, some of which do not necessarily include EGFR itself (Sun et al., 2011), these findings highlight the need to understand network connectivity and dynamics (Pawson and Linding, 2008). Conversely, these observations suggest that EGFR phosphorylation may constitute a useful biomarker of response to time-staggered inhibition in at least some tumor types that are EGFR driven, including some TNBCs and lung cancers.

A key consequence of the erlotinib-dependent dynamic remodeling of the DDR network is activation of caspase-8 following DNA damage. The mechanism of caspase-8 activation is unclear because it is generally thought to be specific to receptor-mediated apoptosis triggered by ligands such as the tumor necrosis factor (TNF) and TNF-related apoptosis-inducing...
ligand (TRAIL). Possibilities include feedback activation by caspase-3, possibly involving caspase-6 (Albeck et al., 2008); direct activation of death receptors by DDR proteins (Yoon et al., 2009); or an autocrine/paracrine mechanism involving an as-yet unidentified death ligand. Distinguishing between these and other possibilities will be a focus for future studies.

Combinatorial drug effects are complex, even for relatively specific drugs like EGFR inhibitors. Our understanding of compensation and network rewiring is currently not sufficient to allow a priori predictions of the cellular response, particularly in cancer cells in which signaling networks often exist in atypical forms. Our work highlights the utility of experimental examination of time-staggered combination treatments for their anticancer effects, particularly when combined with an analysis of signaling pathways and responses using mathematical modeling. These types of approaches may facilitate the identification of efficacious drug combinations and new therapeutic targets and also the design of different types of clinical trials to study the killing of oncogene-addicted tumors through drug-induced dynamic rewiring of signaling pathways.

**EXPERIMENTAL PROCEDURES**

**Cellular Response Assays**

**Apoptosis**

Following the treatment time course, cells were washed, trypsinized, fixed in 4% paraformaldehyde for 15 min at room temperature, resuspended in ice-cold methanol, and incubated overnight at –20°C. Cells were then washed twice in PBS-Tween and stained with antibodies against cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP). Secondary Alexa-conjugated antibodies were used for visualization in a BD FacsCalibur flow cytometer.

**Cell-Cycle Analysis**

Cells were fixed in 70% ethanol overnight at –20°C, permeabilized with 0.25% Triton X-100 for 20 min at 4°C, blocked with 1% BSA, and incubated with anti-phospho-histone H3. Following washing, cells were incubated with Alexa488-conjugated secondary antibody on ice, washed, and stained with propidium iodide (PI) prior to analysis. Data were analyzed using the Dean-Jett-Fox algorithm.

**Cell Viability/Proliferation**

Cells were plated at 5,000 cells per well in 96-well plates. Metabolic viability was determined using CellTiterGlo (Promega) according to the manufacturer’s protocol.

**Western Blotting and Antibodies**

Cells were lysed in a manner that would allow samples to be used for both western blot analysis and reverse-phase protein microarray. See Extended Experimental Procedures for a detailed description of the cell lysis protocol and antibodies used in this study. Data generated by quantitative western blot were preprocessed prior to use in computational modeling. Raw signals for each protein target of interest were quantified and background subtracted using the Li-COR Odyssey software and divided by β-actin signals to normalize for loading differences, and then each normalized signal was divided by a reference sample contained on each gel for gel-to-gel normalization.

**Reverse-Phase Protein Microarray**

Reverse-phase protein microarrays were printed on a fee-for-service basis through the MIT BioMicro Center. Microarray data were obtained from three independent biological replicates per time point and analyzed using linear model for microarray (LIMMA).

**Immunofluorescence Microscopy**

Cells were seeded onto coverslips and treated for the indicated times. For autophagy analysis, cells were stably transfected with an mCHERRY-GFP-LC3 reporter construct. Cells were fixed and stained with primary antibody targeting either p-H2AX or 53BP1 and DAPI as above. Data reported are integrated intensity of pH2AX or 53BP1 foci per nucleus. For autophagy measurements, cells were scored positive if the number of GFP and mCHERRY puncta significantly increased relative to untreated cells. Approximately 100 cells were counted in a double-blind fashion per condition. Each experiment was performed in experimental triplicate.

**RNA Expression Analysis by Microarray**

RNA was extracted from cells using the RNeasy Kit (QIAGEN). Affymetrix Human U133 Plus 2.0 microarrays were hybridized, labeled, and processed on a fee-for-service basis through the MIT BioMicro Center. Microarray data have been obtained from three independent biological replicates per time point and analyzed using linear model for microarray (LIMMA).

**Computational Modeling and Statistics**

Unless otherwise noted, all statistical analyses were performed using Graphpad Prism, and graphs were created using Microsoft Excel, Spotfire, Matlab, DataRail, or SIMCA-P. Analysis of flow cytometry data was performed using Flowjo. Analysis of RNA expression microarray data was performed using either GSEA or GeneGO as indicated.

**Data-Driven Modeling**

Data-driven modeling and the application of partial least-squares to biological data have been described in detail previously (Janes and Yaffe, 2006). All data were variance scaled to nondimensionalize the different measurements. Model predictions were made via cross-validation. Model fitness was calculated using R², Q², and RMSE, as described previously by Gaudet et al. (2005). VIP was calculated following Janes et al. (2008).

**Xenograft Tumor Model**

For in vivo tumor regression assays, 10⁷ BT-20 cells in PBS were mixed 1:1 with matrigel on ice and injected subcutaneously into the hindflanks of nude mice (NCR nu/nu, Taconic). Tumors were allowed to form for 7 days. Mice were then treated intraperitoneally with doxorubicin (4 mg/kg) or a combination of doxorubicin and erlotinib (25 mg/kg), with erlotinib either given at the same time as doxorubicin (D/E) or given 8 hr prior to doxorubicin (E → D). Tumors were monitored for 14 days after the treatment phase, and volume was estimated using the ½ L × W² formula. These experiments were approved by the Massachusetts Institute of Technology Committee on Animal Care (CAC).

**ACCESSION NUMBERS**

Expression data can be found in the GEO repository under the accession number GSE30516.

**SUPPLEMENTAL INFORMATION**

Supplemental information includes Extended Experimental Procedures, seven figures, and one table and can be found with this article online at doi:10.1016/j.cell.2012.03.031.

**ACKNOWLEDGMENTS**

We thank Sandra Morandell, Kylie Huang, Jose McFaline, and Jessica Reddy for technical assistance in the early stages of this study and the Swanson Biotechnology Center at the Koch Institute for their technical support, including Eliza Vasile (microscopy), Glen Paradis (flow cytometry), and especially Charlie Whittaker (bioinformatics) for his guidance in analyzing microarray experiments. We further thank Doug Lauffenburger and members of the CDP community for fruitful discussions and advice throughout the development and execution of this study. This work was supported by NIH grants CA112967 and GM68762 to P.K.S. and M.B.Y, ES015339 to M.B.Y., and DOD fellowship BC097884 to M.J.L, P.K.S., G.M., and M.B.Y. are founders and shareholders of Merrimack Pharmaceuticals. P.K.S. and M.B.Y. are scientific advisory board members, and G.M. is a current employee. G.M. is also a scientific advisory board member of Aushon Biosystems.
REFERENCES


